Search research articles
Contact Us
Filters
Showing results (181-190 of 224) with videos related to
Page
of 23
Sort By:
Cell Death and Differentiation
|
April 23, 2022
IRF4 deficiency vulnerates B-cell progeny for leukemogenesis via somatically acquired Jak3 mutations conferring IL-7 hypersensitivity
Dennis Das Gupta, Christoph Paul, Nadine Samel, et al.
Blood
|
May 8, 2024
Decitabine in older patients with AML: quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase 3 trial
Fabio Efficace, Michal Kicinski, Corneel Coens, et al.
Blood
|
November 1, 2011
Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV
Alice Fabarius, Armin Leitner, Andreas Hochhaus, et al.
Hemasphere
|
July 10, 2023
Radiation and Dose-densification of R-CHOP in Primary Mediastinal B-cell Lymphoma: Subgroup Analysis of the UNFOLDER Trial
Gerhard Held, Lorenz Thurner, Viola Poeschel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 4, 2013
Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV
Rüdiger Hehlmann, Martin C Müller, Michael Lauseker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 4, 2019
Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II Trial
Michael Lübbert, Olga Grishina, Claudia Schmoor, et al.
Journal of Cancer Research and Clinical Oncology
|
September 28, 2022
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry
Maher Hanoun, Leo Ruhnke, Michael Kramer, et al.
The New England Journal of Medicine
|
October 31, 2019
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i>-Mutated AML
Alexander E Perl, Giovanni Martinelli, Jorge E Cortes, et al.
British Journal of Cancer
|
August 4, 2023
Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy: a real-world registry experience
Julius C Enßle, Sebastian Wolf, Sebastian Scheich, et al.
Journal of Hematology & Oncology
|
July 22, 2023
Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial
Maria-Luisa Schubert, Anita Schmitt, Angela Hückelhoven-Krauss, et al.
Page
of 23
Search research articles
Search
Showing results (181-190 of 224) with videos related to
Sort By:
Page
of 23
Cell Death and Differentiation
|
April 23, 2022
IRF4 deficiency vulnerates B-cell progeny for leukemogenesis via somatically acquired Jak3 mutations conferring IL-7 hypersensitivity
Dennis Das Gupta, Christoph Paul, Nadine Samel, et al.
Blood
|
May 8, 2024
Decitabine in older patients with AML: quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase 3 trial
Fabio Efficace, Michal Kicinski, Corneel Coens, et al.
Blood
|
November 1, 2011
Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV
Alice Fabarius, Armin Leitner, Andreas Hochhaus, et al.
Hemasphere
|
July 10, 2023
Radiation and Dose-densification of R-CHOP in Primary Mediastinal B-cell Lymphoma: Subgroup Analysis of the UNFOLDER Trial
Gerhard Held, Lorenz Thurner, Viola Poeschel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 4, 2013
Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV
Rüdiger Hehlmann, Martin C Müller, Michael Lauseker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 4, 2019
Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II Trial
Michael Lübbert, Olga Grishina, Claudia Schmoor, et al.
Journal of Cancer Research and Clinical Oncology
|
September 28, 2022
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry
Maher Hanoun, Leo Ruhnke, Michael Kramer, et al.
The New England Journal of Medicine
|
October 31, 2019
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i>-Mutated AML
Alexander E Perl, Giovanni Martinelli, Jorge E Cortes, et al.
British Journal of Cancer
|
August 4, 2023
Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy: a real-world registry experience
Julius C Enßle, Sebastian Wolf, Sebastian Scheich, et al.
Journal of Hematology & Oncology
|
July 22, 2023
Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial
Maria-Luisa Schubert, Anita Schmitt, Angela Hückelhoven-Krauss, et al.
Page
of 23